The central question is no longer whether we can innovate, but whether innovation can truly reach patients in time.
4h
Diamyd Medical Announces Finalization Of Database For Interim Analysis In Phase 3 DIAGNODE-3 Trial
Diamyd Medical Announces Finalization Of Database For Interim Analysis In Phase 3 DIAGNODE-3 Trial. STOCKHOLM, Feb. 24, 2026 /PRNewswire/ -- The clinical database has been finalized for the pre-specif ...
The clinical database has been finalized for the pre-specified interim efficacy analysis in Diamyd Medical's ongoing pivotal Phase 3 trial (DIAGNODE-3) evaluating retogatein (rhGAD65) in individuals w ...
Lionheart Health, Inc. announces a USPTO Letter of Allowance for its patented bioelectric technology designed to upregulate GDF10 and complementary regenerative proteins, supporting investigational ...
In an analysis of therapeutic interventions following the failure of chimeric antigen receptor (CAR) T-cell therapy, Rahul ...
Seedless fruits are highly valued for their superior edible quality and consumer appeal, yet the biological mechanisms that allow fruits to develop ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results